Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.

Autor: Sonia Vibhakar Patel, Dushyantha T Jayaweera, Keri N Althoff, Joseph J Eron, Janna Radtchenko, Anthony Mills, Graeme Moyle, Steven Santiago, Paul E Sax, Jason Gillman, Karam Mounzer, Richard A Elion, Gregory D Huhn

Publikováno v: PLoS ONE, Vol 15, Iss 2, p e0228847 (2020)

The advent of direct-acting antiviral (DAA) therapies has dramatically transformed HCV treatment, with most recent trials demonstrating high efficacy rates (>90%) across all genotypes and special populations, including patients with HIV/HCV coinfecti

Externí odkaz: https://doaj.org/article/3f03854a3efb4042a1a0352f586949cf

Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.

Autor: Josep M Llibre, François Raffi, Graeme Moyle, Georg Behrens, Stephane Bouee, Geraldine Reilly, Peter Borg, David Piontkowsky, Felipe Rogatto

Publikováno v: PLoS ONE, Vol 11, Iss 7, p e0159286 (2016)

[This corrects the article DOI: 10.1371/journal.pone.0155406.].

Externí odkaz: https://doaj.org/article/2532b997de224cba859bcee8fc3d5115

Short Communication: Predictive Value of HIV-Related Versus Traditional Risk Factors for Coronary Atherosclerosis in People Aging with HIV

Autor: Branca Pereira, Ana Milinkovic, Marta Boffito, Graeme Moyle, Sundhiya Mandalia, Abtehale Al-hussaini, Maria Mazzitelli

Publikováno v: AIDS Research and Human Retroviruses. 38:80-86

BACKGROUND Cardiovascular disease (CVD) is an important cause of morbidity in people living with HIV (PLWH). We compared the predictive value of HIV-related and traditional CVD risk factors to assess which factors best predict the presence of subclin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdfa2944ab3f059f02fedb6883800811
https://doi.org/10.1089/aid.2021.0064

Evolocumab in HIV-Infected Patients With Dyslipidemia

Autor: Franck Boccara, Princy N. Kumar, Bruno Caramelli, Alexandra Calmy, J. Antonio G. López, Sarah Bray, Marcoli Cyrille, Robert S. Rosenson, David Baker, Mark Bloch, Robert Finlayson, Jennifer Hoy, Kenneth Koh, Norman Roth, Stephane De Wit, Eric Florence, Linos Vandekerckhove, Jose Valdez Ramalho Madruga, Sandra Wagner Cardoso, Greg Bondy, Michael Gill, George Tsoukas, Sylvie Trottier, Marek Smieja, Christine Katlama, Fabrice Bonnet, Francois Raffi, Laurent Cotte, Jean-Michel Molina, Jacques Reynes, Antonios Papadopoulos, Simeon Metallidis, Vassilios Paparizos, Vasileios Papastamopoulos, Cristina Mussini, Massimo Galli, Andrea Antinori, Antonio Di Biagio, Pierluigi Viale, Andrzej Horban, Nuno Marques, Daniel Coutinho, Joaquim Oliveira, Paula Freitas, Liliana-Lucia Preotescu, Iosif Marincu, Rodica Silaghi, Sorin Rugina, Noluthando Mwelase, Sheena Kotze, Jose Ignacio Bernardino de la Serna, Vicente Estrada Perez, Esteban Martinez, Adrian Curran, Dominique Laurent Braun, Enos Bernasconi, Matthias Cavassini, John Walsh, Julie Fox, Graeme Moyle, Robert Rosenson, Jamie Morano, Jason Baker, Gerald Pierone, Carl Fichtenbaum, Paul Benson, Deborah Goldstein, Joseph Sacco, Princy Kumar, Robert Grossberg, Kara Chew, Christopher DeFilippi, Vilma Drelichman, Norman Markowitz, David Parenti, Katherine Doktor, Paul Thompson

Publikováno v: Journal of the American College of Cardiology. 75:2570-2584

Background People living with HIV (PLHIV) are at increased risk of atherosclerotic cardiovascular disease (ASCVD) and prone to statin-related adverse events from drug-drug interactions with certain antiretroviral regimens. Objectives This study sough

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::de4c638f1c99a5aa5c7fc8cce88a955f
https://doi.org/10.1016/j.jacc.2020.03.025

Limited weight impact after switching from boosted protease inhibitors to dolutegravir in persons with HIV with high cardiovascular risk: a post hoc analysis of the 96-week NEAT-022 randomized trial

Autor: Laura, Waters, Lambert, Assoumou, Ana, González-Cordón, Stefano, Rusconi, Pere, Domingo, Mark, Gompels, Stephane, de Wit, François, Raffi, Christoph, Stephan, Mar, Masiá, Jürgen, Rockstroh, Christine, Katlama, Georg M N, Behrens, Graeme, Moyle, Margaret, Johnson, Julie, Fox, Hans-Jürgen, Stellbrink, Giovanni, Guaraldi, Eric, Florence, Stefan, Esser, José M, Gatell, Anton, Pozniak, Esteban, Martínez

In the NEAT022 trial, virologically suppressed persons with HIV at high cardiovascular risk switching from protease inhibitors to dolutegravir either immediately (DTG-I) or after 48 weeks (DTG-D) showed non-inferior virological suppression and signif

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::b1b9b94fa8d43eac38701bf985d32767
https://hdl.handle.net/11380/1295531